Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UK HARP-III: LCZ696 vs irbesartan in chronic kidney disease
2013-004205-89Phase 2Completed
- Sponsor
- Oxford University Hospitals
- Start
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of sacubitril + valsartan in chronic kidney disease (CKD) and kidney failure (2 arms), sponsored by Oxford University Hospitals. Primary endpoint: Change in measured glomerular filtration rate at 12 months. Started Jul 2014; status: completed.
02
Drugs
sacubitril + valsartan
03
Conditions
chronic kidney disease (CKD)kidney failure
Beyond the preview
Go deeper on 2013-004205-89.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004205-89.